Emerging niche business cluster eyes challenge
Manx-based BioMed Pharmacovigilance firm Panacea says there are risks posed by Brexit to the sector on the Isle of Man.
The company gathers, monitors and analyses medicines as they hit the market, and has been waxing lyrical about the Island's BioMed environment in the UK press recently.
It's been working within what it describes as the 'burgeoning' Manx cluster of specialist companies, and with the Isle of Man Government, to attract more enterprises to relocate here.
In the post-Brexit landscape, the firm sees both risks and opportunities.
Panacea business development manager Sam Tipper gave a corporate health check as Prime Minister Theresa May prepares to trigger the UK's EU exit:
IOMPO will go from 'strength to strength' in coming years says outgoing chair
Island women asked to shape first State of Style report
Sharp rise in data breaches on Island, says Information Commissioner's Office
First risk assessment on proliferation financing published
